Rajeshkumar, N V <br/><br/>
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2011 
 - 2799-806 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-10-2580  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Pancreatic Ductal--drug therapy<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Drug Synergism<br/>Female<br/>Genes, p53<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Mutation--physiology<br/>Neoplasms--drug therapy<br/>Nuclear Proteins--antagonists & inhibitors<br/>Pancreatic Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Pyrimidinones<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays<br/>Gemcitabine